Literature DB >> 22766006

Differential development of antinociceptive tolerance to morphine and fentanyl is not linked to efficacy in the ventrolateral periaqueductal gray of the rat.

Erin N Bobeck1, Rachel A Haseman, Dana Hong, Susan L Ingram, Michael M Morgan.   

Abstract

UNLABELLED: Systemic administration of morphine typically produces greater tolerance than higher efficacy mu-opioid receptor (MOPr) agonists such as fentanyl. The objective of the present study was to test this relationship by measuring antinociceptive efficacy and tolerance to morphine and fentanyl microinjected into the ventrolateral periaqueductal gray (vlPAG). MOPr agonist efficacy was evaluated by microinjecting the irreversible opioid receptor antagonist β-funaltrexamine hydrochloride (β-FNA) into the vlPAG prior to a dose-response analysis of morphine and fentanyl antinociception. In contrast to systemic administration of morphine and fentanyl, microinjection of these drugs into the vlPAG had similar efficacy as measured by similar reductions in maximal antinociception following β-FNA administration. Analysis of tolerance revealed a rightward shift in the dose-response curve to a single pretreatment with morphine, but not fentanyl. The magnitude of tolerance to morphine was comparable following 1, 4, or 8 pretreatments. Tolerance to fentanyl also was evident following 4 or 8 microinjections. These data are surprising in that antinociceptive efficacy appears to vary depending on the site of administration. Moreover, the similar efficacy following microinjection of morphine and fentanyl into the vlPAG was associated with comparable tolerance, with the 1 exception of no tolerance to acute administration of fentanyl. PERSPECTIVE: These data reveal that antinociceptive tolerance following vlPAG administration of opioids develops rapidly and is evident with both morphine and fentanyl, and the magnitude is relatively consistent regardless of the number of pretreatments.
Copyright © 2012 American Pain Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22766006      PMCID: PMC3958948          DOI: 10.1016/j.jpain.2012.05.005

Source DB:  PubMed          Journal:  J Pain        ISSN: 1526-5900            Impact factor:   5.820


  36 in total

Review 1.  Spinal plasticity of acute opioid tolerance.

Authors:  C A Fairbanks; G L Wilcox
Journal:  J Biomed Sci       Date:  2000 May-Jun       Impact factor: 8.410

2.  Potency of infused spinal antinociceptive agents is inversely related to magnitude of tolerance after continuous infusion.

Authors:  C W Stevens; T L Yaksh
Journal:  J Pharmacol Exp Ther       Date:  1989-07       Impact factor: 4.030

3.  Synergistic analgesic interactions between the periaqueductal gray and the locus coeruleus.

Authors:  R Bodnar; D Paul; G W Pasternak
Journal:  Brain Res       Date:  1991-09-06       Impact factor: 3.252

4.  Tolerance to morphine microinjections in the periaqueductal gray (PAG) induces tolerance to systemic, but not intrathecal morphine.

Authors:  J A Siuciak; C Advokat
Journal:  Brain Res       Date:  1987-10-27       Impact factor: 3.252

5.  Paradoxical effects after microinjection of morphine in the periaqueductal gray matter in the rat.

Authors:  Y F Jacquet; A Lajtha
Journal:  Science       Date:  1974-09-20       Impact factor: 47.728

6.  The periaqueductal gray: site of morphine analgesia and tolerance as shown by 2-way cross tolerance between systemic and intracerebral injections.

Authors:  Y F Jacquet; A Lajtha
Journal:  Brain Res       Date:  1976-02-27       Impact factor: 3.252

7.  The role of beta-arrestin2 in the severity of antinociceptive tolerance and physical dependence induced by different opioid pain therapeutics.

Authors:  Kirsten M Raehal; Laura M Bohn
Journal:  Neuropharmacology       Date:  2010-08-14       Impact factor: 5.250

8.  Characteristics of dose-dependent antagonism by beta-funaltrexamine of the antinociceptive effects of intrathecal mu agonists.

Authors:  E Mjanger; T L Yaksh
Journal:  J Pharmacol Exp Ther       Date:  1991-08       Impact factor: 4.030

9.  Mu-opioid receptor desensitization in mature rat neurons: lack of interaction between DAMGO and morphine.

Authors:  Christopher P Bailey; Daniel Couch; Elizabeth Johnson; Katie Griffiths; Eamonn Kelly; Graeme Henderson
Journal:  J Neurosci       Date:  2003-11-19       Impact factor: 6.167

10.  Time course characteristics of tolerance development to continuously infused antinociceptive agents in rat spinal cord.

Authors:  C W Stevens; T L Yaksh
Journal:  J Pharmacol Exp Ther       Date:  1989-10       Impact factor: 4.030

View more
  14 in total

Review 1.  Inflammatory mediators of opioid tolerance: Implications for dependency and addiction.

Authors:  Lori N Eidson; Anne Z Murphy
Journal:  Peptides       Date:  2019-03-16       Impact factor: 3.750

2.  Entanglement between thermoregulation and nociception in the rat: the case of morphine.

Authors:  Nabil El Bitar; Bernard Pollin; Elias Karroum; Ivanne Pincedé; Daniel Le Bars
Journal:  J Neurophysiol       Date:  2016-09-07       Impact factor: 2.714

3.  Lack of Antinociceptive Cross-Tolerance With Co-Administration of Morphine and Fentanyl Into the Periaqueductal Gray of Male Sprague-Dawley Rats.

Authors:  Erin N Bobeck; Shauna M Schoo; Susan L Ingram; Michael M Morgan
Journal:  J Pain       Date:  2019-03-07       Impact factor: 5.820

4.  Enhanced antinociception with repeated microinjections of apomorphine into the periaqueductal gray of male and female rats.

Authors:  Shauna M Schoo; Erin N Bobeck; Michael M Morgan
Journal:  Behav Pharmacol       Date:  2018-04       Impact factor: 2.293

5.  Relative contribution of the dorsal raphe nucleus and ventrolateral periaqueductal gray to morphine antinociception and tolerance in the rat.

Authors:  Kyle N Campion; Kimber A Saville; Michael M Morgan
Journal:  Eur J Neurosci       Date:  2016-09-14       Impact factor: 3.386

6.  Ligand-biased activation of extracellular signal-regulated kinase 1/2 leads to differences in opioid induced antinociception and tolerance.

Authors:  Erin N Bobeck; Susan L Ingram; Sam M Hermes; Sue A Aicher; Michael M Morgan
Journal:  Behav Brain Res       Date:  2015-10-20       Impact factor: 3.332

7.  Chronic inflammatory pain prevents tolerance to the antinociceptive effect of morphine microinjected into the ventrolateral periaqueductal gray of the rat.

Authors:  Melissa L Mehalick; Susan L Ingram; Sue A Aicher; Michael M Morgan
Journal:  J Pain       Date:  2013-10-22       Impact factor: 5.820

8.  Blockade of Toll-like receptor 4 attenuates morphine tolerance and facilitates the pain relieving properties of morphine.

Authors:  Lori N Eidson; Anne Z Murphy
Journal:  J Neurosci       Date:  2013-10-02       Impact factor: 6.167

9.  Contribution of adenylyl cyclase modulation of pre- and postsynaptic GABA neurotransmission to morphine antinociception and tolerance.

Authors:  Erin N Bobeck; QiLiang Chen; Michael M Morgan; Susan L Ingram
Journal:  Neuropsychopharmacology       Date:  2014-03-13       Impact factor: 7.853

10.  Change in functional selectivity of morphine with the development of antinociceptive tolerance.

Authors:  T A Macey; E N Bobeck; K L Suchland; M M Morgan; S L Ingram
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.